Koneksa has teamed up with Beacon Biosignals for a clinical trial to assess the integration of the latter’s at-home electroencephalogram (EEG) into its Neuroscience Solution Toolkit.
The Beacon Platform unlocks longitudinal EEG technology and leverages machine-learning algorithms to increase insights into brain activity, helping sponsors to gain comprehensive data analysis and data visualisation capabilities.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Referred to as LEARNS, the Koneksa-sponsored, syndicated and observational study has been designed for identifying biomarkers and determining the validity and usability measures of sleep and neurologic disorders collected using smartphones, at-home EEG and wearables.
The trial will compare the Koneksa neuroscience solution and the Beacon Biosignals platform for at-home EEG, with in-clinic polysomnography, in neurological and sleep disorders.
Parkinson’s, Alzheimer’s and Huntington’s, as well as mild cognitive impairment, obstructive sleep apnoea and narcolepsy are the current cohorts in the LEARNS study.
Koneksa chief medical officer John Wagner said: “Beacon’s mobile EEG will join more than a dozen digital health technologies that are already integrated into the Koneksa solution.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe trial will measure the validity of smartphone-based motor, speech and cognitive assessments against gold-standard tools.
Furthermore, it will evaluate whether assessment combinations hold the potential to detect diagnostic features at the cohort diagnostic boundary.
Beacon Biosignals co-founder and CEO Dr Jacob Donoghue said: “With our shared science-first ethos, we are united in our relentless pursuit to develop cutting-edge tools that revolutionise drug development and accelerate the delivery of life-changing therapies to patients.”
